Jieli Han
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
-
- Psoriasis: Treatment and Pathogenesis
Papers in
- Oncology 6
- Cytokine Signaling Pathways and Interactions 3
- Cancer Immunotherapy and Biomarkers 2
- Cancer Cells and Metastasis 1
-
- Psoriasis: Treatment and Pathogenesis 3
- Toxin Mechanisms and Immunotoxins 1
- Co-authors
- Jinshuo Fan (8 shared papers)Feng Wu (8 shared papers)Zhilei Lv (8 shared papers)Yang Jin (8 shared papers)Guorong Hu (7 shared papers)Mengfei Guo (7 shared papers)Qi Huang (7 shared papers)Juanjuan Xu (4 shared papers)
In The Last Decade
Jieli Han
8 papers receiving 386 citations
Peers
Comparison fields: 5 of 73
- Oncology 145
- Immunology 97
- Cancer Research 63
- Infectious Diseases 34
- Cardiology and Cardiovascular Medicine 33
Countries citing papers authored by Jieli Han
This map shows the geographic impact of Jieli Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieli Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieli Han more than expected).
Fields of papers citing papers by Jieli Han
This network shows the impact of papers produced by Jieli Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieli Han. The network helps show where Jieli Han may publish in the future.
Co-authors
The 19 scholars most cited alongside Jieli Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 96 | |
| 2 | 2016 | 94 | |
| 3 | 2016 | 75 | |
| 4 | 2016 | 52 | |
| 5 | IL-17 induces EMT via Stat3 in lung adenocarcinoma. | 2016 | 38 |
| 6 | 2015 | 14 | |
| 7 | 2014 | 10 | |
| 8 | 2015 | 10 |
About Jieli Han
Jieli Han is a scholar working on Oncology, Immunology, Biotechnology, Cancer Research and Endocrinology, Diabetes and Metabolism, having authored 8 papers that have together received 389 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (3 papers), Cytokine Signaling Pathways and Interactions (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Toxin Mechanisms and Immunotoxins (1 paper), Renin-Angiotensin System Studies (1 paper), Cancer Cells and Metastasis (1 paper), Cancer Research and Treatments (1 paper) and Metastasis and carcinoma case studies (1 paper). The work is most often cited by research in Oncology (145 citations), Immunology (97 citations), Cancer Research (63 citations), Infectious Diseases (34 citations) and Cardiology and Cardiovascular Medicine (33 citations). Jieli Han has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Jinshuo Fan, Feng Wu, Zhilei Lv, Yang Jin, Guorong Hu, Mengfei Guo, Qi Huang, Juanjuan Xu, Limin Duan and Xiuxiu Zhang. Their work appears in journals such as Scientific Reports, Medical Oncology, Journal of Cancer Research and Clinical Oncology, Cancer Biomarkers and Frontiers in Physiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.